YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)
Parker Waichman Alonso LLP Headlines by Topic
Procrit
Procrit, Aranesp, Epogen Could be Restricted by FDA
Mar 12, 2008 | Parker Waichman Alonso LLP
Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients, could soon have new restrictions imposed on them by the Food and Drug...
Aranesp, Epogen, Procrit Get Another Black Box Warning
Mar 10, 2008 | Parker Waichman Alonso LLP
Aranesp, Epogen and Procrit, drugs used to treat anemia in patients undergoing chemotherapy, will soon bear new black box warnings that they may...
Epogen, Aranesp and Procrit Linked to Potentially Fatal Blood Clots
Feb 27, 2008 | Parker Waichman Alonso LLP
Epogen, Aranesp and Procrit, anemia drugs used to treat cancer patients, have been linked to a higher risk of a potentially fatal type of blood...
Aranesp, Epogen and Procrit Policy Justified, Medicare Official Says.
Feb 11, 2008 | Parker Waichman Alonso LLP
More trouble for Aranesp, Epogen and Procrit. Senior Medicare official Dr. Barry Straube said evidence—including two studies—is...
Procrit, Aranesp and Epogen to See More FDA Scrutiny After Two Studies Show Increased Tumor Growth in Some Cancer Patients Treated with ESAs
Jan 3, 2008 | Parker Waichman Alonso LLP
Two new studies suggest that Procrit, Aranesp and Epogen could carry more risks than first thought, prompting the Food & Drug Administration...
Aranesp, Epogen and Procrit Linked to Leukemia in Some Patients
Dec 11, 2007 | Parker Waichman Alonso LLP
Aranesp, Epogen and Procrit have been linked to yet another deadly side effect. New research suggests that the anemia drugs, known as...
Amgen Warns of More Aranesp Lable Changes
Dec 10, 2007 | Parker Waichman Alonso LLP
Aranesp, an anemia drug often used to treat chemotherapy patients, could soon have safety information on its label updated yet again, the...
Aranesp Study Shows Little Benefit for Breast Cancer Patients, Possibly Higher Rates of Death, Tumor Growth
Dec 3, 2007 | Parker Waichman Alonso LLP
Aranesp, an anemia drug, does not appear to benefit breast cancer patients. Amgen Inc., maker of Aranesp, recently said interim results...
Aranesp, Epogen, Procrit Label Updated Over Safety Concerns
Nov 8, 2007 | Parker Waichman Alonso LLP
The labels of Aranesp, Epogen and Procrit, drugs used to treat anemia, are being updated to include new dosage guidelines and specific information on...
Proposed Aranesp, Epogen, Procrit Dosage Limit Rejected by FDA Advisory Panel
Sep 12, 2007 | Parker Waichman Alonso, LLP
An advisory panel has concluded that Amgen's anemia medications should not be subject to a new dosage limit proposed by the Food & Drug...
Defective Drugs
